Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 5/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.41 |
| ▸ | PDE4A | P27815 | 5/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | PTGFR | P43088 | 1/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32677593 | 1.00 | NAPRT (0.46) | NAPRTHCAR2CYP4F2CYP4A11PDE4A | |
| SCHEMBL31076279 | 0.81 | FFAR4 (0.41) | CYP4F2CYP4A11PDE4APDE4BPDE4C | |
| SCHEMBL29302487 | 0.81 | SMN1; SMN2 (0.46) | CYP4F2CYP4A11PDE4APDE4BPDE4C | |
| SCHEMBL32677629 | 0.79 | CYP2C19 (0.43) | NAPRT | |
| SCHEMBL1666614 | 0.77 | FFAR1 (0.41) | NAPRTFFAR1NR4A2RXRARXRB | |
| SCHEMBL1666615 | 0.77 | FFAR1 (0.41) | NAPRTFFAR1NR4A2RXRARXRB | |
| SCHEMBL5675799 | 0.76 | KDM1A (0.53) | FFAR1DRD2DRD1TBXA2RDRD4 | |
| SCHEMBL4133939 | 0.76 | KDM1A (0.53) | FFAR1DRD2DRD1TBXA2RDRD4 | |
| SCHEMBL31332619 | 0.76 | KDM1A (0.53) | FFAR1DRD2DRD1TBXA2RDRD4 | |
| SCHEMBL3420686 | 0.76 | KDM1A (0.53) | FFAR1DRD2DRD1TBXA2RDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2026041636-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2026-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CCR6 | NAPRT 3188/4885HCAR2 551/4885CYP4F2 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.